Key References
- Borel, JF Feurer, C Magnee, C Stahelin, H Effects of the new antilymphocytic peptide cyclosporin A in animals. Immunology 1977 32 1017–1025.
- White, DJ Calne, RY Plumb, A Mode of action of cyclosporin A: A new immunosuppressive agent. Transplant. Proc. 1979 11 855–859.
- Van den Bogaerde, J Strategies for the prevention of graft rejection. Curr Opin. Thera. Patents 1992 2 463–476.
- Apperley, JF Jones, L Hale, G Waldman, H Hows, J Rombos, Y Tsatalas, C Marcus, RE Goolden, AW Gordon Smith, E Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant. 1986 1 53–66.
- Waldman, H Polliak, A Hale, G Or, R Cividalli, G Weiss, L Weshler, Z Samuel, S Manor, D Brautbar, C Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984 2 483–486.
- Cerilli, JG Highlights of recent progress in transplantation Organ transplantation and replacement. Cerilli, GJ JB Lippincot Company Philadelphia 1988 l6–36.
- Morris, RE Rapamycin: FK506's fraternal twin or distant cousin? Immunol. Today 1991 12 137–140.
- Randak, C Brabletz, T Hergenrother, M Sobotta, I Serfling, E Cyclosporin A suppresses the expression of the interleukin 2 gene by inhibiting the binding of lymphocyte-specific factors to the IL-2 enhancer. Embo J. 1990 9 2529–2536.